This company listing is no longer active
Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
OKYO Pharma Gelecekteki Büyüme
Future kriter kontrolleri 3/6
OKYO Pharma is forecast to grow earnings and revenue by 109.7% and 149.8% per annum respectively while EPS is expected to grow by 147.9% per annum.
Anahtar bilgiler
109.7%
Kazanç büyüme oranı
147.9%
EPS büyüme oranı
Biotechs kazanç büyümesi | 35.0% |
Gelir büyüme oranı | 149.8% |
Gelecekteki özkaynak getirisi | n/a |
Analist kapsamı | Low |
Son güncelleme | 16 Feb 2023 |
Gelecekteki son büyüme güncellemeleri
Güncelleme yok
Recent updates
Kazanç ve Gelir Büyüme Tahminleri
Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
---|---|---|---|---|---|
3/31/2025 | 13 | 6 | 4 | 4 | 1 |
3/31/2024 | N/A | -7 | -6 | -6 | 1 |
3/31/2023 | N/A | -13 | -8 | -8 | N/A |
12/31/2022 | N/A | -11 | -7 | -7 | N/A |
9/30/2022 | N/A | -7 | -5 | -5 | N/A |
6/30/2022 | N/A | -5 | -4 | -4 | N/A |
3/31/2022 | N/A | -5 | -5 | -5 | N/A |
12/31/2021 | N/A | -5 | -5 | -5 | N/A |
9/30/2021 | N/A | -4 | -3 | -3 | N/A |
6/30/2021 | N/A | -3 | -2 | -2 | N/A |
3/31/2021 | N/A | -3 | -2 | -2 | N/A |
12/31/2020 | N/A | -1 | -1 | -1 | N/A |
9/30/2020 | N/A | 0 | -1 | -1 | N/A |
6/30/2020 | N/A | -1 | -1 | -1 | N/A |
3/31/2020 | N/A | -1 | -1 | -1 | N/A |
12/31/2019 | N/A | -3 | N/A | N/A | N/A |
9/30/2019 | N/A | -4 | -2 | -2 | N/A |
6/30/2019 | N/A | -4 | -2 | -2 | N/A |
3/31/2019 | N/A | -4 | -2 | -2 | N/A |
12/31/2018 | N/A | -3 | N/A | N/A | N/A |
9/30/2018 | N/A | -2 | -2 | -2 | N/A |
6/30/2018 | N/A | -11 | -1 | -1 | N/A |
3/31/2018 | N/A | -20 | -1 | -1 | N/A |
12/31/2017 | N/A | -20 | -1 | -1 | N/A |
9/30/2017 | N/A | -19 | -1 | -1 | N/A |
6/30/2017 | N/A | -10 | -1 | -1 | N/A |
3/31/2017 | N/A | 0 | -1 | -1 | N/A |
12/31/2016 | N/A | 0 | N/A | 0 | N/A |
9/30/2016 | N/A | 0 | N/A | 0 | N/A |
6/30/2016 | N/A | -1 | N/A | 0 | N/A |
3/31/2016 | N/A | -1 | N/A | 0 | N/A |
9/30/2015 | N/A | -1 | N/A | -1 | N/A |
6/30/2015 | N/A | -1 | N/A | -1 | N/A |
3/31/2015 | N/A | -1 | N/A | -1 | N/A |
12/31/2014 | N/A | -4 | N/A | -1 | N/A |
9/30/2014 | N/A | -3 | N/A | -2 | N/A |
6/30/2014 | N/A | -6 | N/A | -2 | N/A |
3/31/2014 | N/A | -8 | N/A | -2 | N/A |
12/31/2013 | N/A | -8 | N/A | -2 | N/A |
9/30/2013 | N/A | -8 | N/A | -2 | N/A |
6/30/2013 | N/A | -5 | N/A | -2 | N/A |
3/31/2013 | N/A | -3 | N/A | -3 | N/A |
12/31/2012 | N/A | -3 | N/A | -2 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: OK10 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.4%).
Kazançlar ve Piyasa: OK10 is forecast to become profitable over the next 3 years, which is considered above average market growth.
Yüksek Büyüme Kazançları: OK10 is expected to become profitable in the next 3 years.
Gelir ve Pazar: OK10 is forecast to have no revenue next year.
Yüksek Büyüme Geliri: OK10 is forecast to have no revenue next year.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: Insufficient data to determine if OK10's Return on Equity is forecast to be high in 3 years time